Malaysia

Pharmaniaga to manufacture Covid-19 vaccine starting March

Local pharmaceutical plant able to produce two million doses of Sinovac per month

Updated 5 years ago · Published on 12 Jan 2021 1:52PM

 Pharmaniaga to manufacture Covid-19 vaccine starting March
The Sinovac vaccine will be the first to be manufactured in Malaysia at a Pharmaniaga Bhd subsidiary plant in Puchong. – AFP pic, January 12, 2021

KUALA LUMPUR – Pharmaniaga Bhd has the capacity to manufacture two million doses of the Covid-19 vaccine developed by Sinovac Life Sciences Co Ltd per month beginning March this year.

Group managing director Datuk Zulkarnain Md Eusope said the vaccine would be the first to be manufactured in Malaysia at the small-volume, injectable, high-tech plant owned by Pharmaniaga’s wholly owned subsidiary, Pharmaniaga LifeSciences Sdn Bhd, in Puchong.

He said the group will invest RM3 million to retrofit the plant to enable the production of the vaccine. 

“We are confident that we can carry out this task successfully, because our technical experts have been working on setting up a halal vaccine plant in Malaysia since 2017,” he said. 

“When Covid-19 spread around the world early last year, we immediately facilitated our team in working with our global partners, including Sinovac, on the fill and finish manufacturing activity and technology transfer to speed up the availability of vaccines against the pandemic,” he told reporters after an agreement was signed between Pharmaniaga and Sinovac Life Sciences today.

The signing ceremony was witnessed by Senior Minister (Security Cluster) and Defence Minister Datuk Seri Ismail Sabri Yaakob, Health Minister Datuk Seri Dr Adham Baba, and Science, Technology and Innovation Minister Khairy Jamaluddin.

Pharmaniaga is set to carry out the fill and finish of the Sinovac Covid-19 vaccine, which is expected to be ready for public distribution by the end of March.

The agreement is for the completion of fill and finish for 14 million doses of the vaccine.

Pharmaniaga has been engaging with the National Pharmaceutical Regulatory Agency (NPRA) to ensure that its plant continues to be in high compliance of regulatory requirements. 

Zulkarnain said the Sinovac vaccine has undergone phase three trials in Brazil and Turkey, and is now in the process of getting approvals in both countries.

“Currently, we are in the discussions with NPRA for registration and they have been very supportive of this project. We are confident that we can manufacture and have the vaccines ready for distribution to hospitals by the end of March this year," he added. 

Meanwhile, Khairy said the agreement between Pharmaniaga and Sinovac is a private initiative.

“We facilitated it because indicated to Pharmaniaga that we are interested in the Sinovac vaccine.

“Now the government’s procurement (of) part of it, hopefully, will be concluded by next week,” he added.

Khairy assured that the vaccine programme for Covid-19 will be carried out within the first quarter of this year.

“We are not too late or too early. We can design our immunisation programme, which can reduce a lot of wastage and be rolled out as efficiently as possible,” he added. – Bernama, January 12, 2021

Related News

Malaysia / 2y

Current health ailments not related to AstraZeneca vaccine, says Noor Hisham

Malaysia / 2y

Govt aware of AstraZeneca vaccine side effects when it was deployed, says Noor Hisham

World / 2y

AstraZeneca Covid-19 vaccine to be withdrawn globally

World / 2y

AstraZeneca admits Covishield can cause blood clots, low platelet count

Malaysia / 3y

8.5 million doses of Covid-19 vaccine worth RM505 mil expired since June 1: PAC

World / 3y

German courts confront suits against vaccine makers BioNTech, AstraZeneca

Spotlight

Malaysia

Khalid urges PAS to ditch Umno alliance and support Anwar

By Alfian Z.M. Tahir

Malaysia

Najib’s house arrest: Govt, AG, Hannah opposed conditional pardon, minutes show

Malaysia

Former Negeri Sembilan exco members end legal fight over removal

Business

Nvidia rules out Jensen Huang comeback as quarterly revenue doubles to US$115b

Malaysia

Indonesia should compensate Malaysians for the prolonged haze – Guan Eng

By Ian McIntyre

Malaysia

Padang Rengas dispute exposes challenge facing possible BN-PN pact

You may be interested

Malaysia

MB’s resignation: “I was not informed” – Jalaluddin

Malaysia

Sabah, Sarawak's local representation in civil service faces Dewan Rakyat scrutiny

Malaysia

Six ordered to attend court over second contempt proceedings in Negeri royal dispute

By Alfian Z.M. Tahir

Malaysia

Nine undocumented Myanmar migrants found after suspect crashes while fleeing police

Malaysia

Secretariat accuses Umno of undermining reconciliation with Negeri Sembilan Palace

By Alfian Z.M. Tahir

Malaysia

Ismail’s resignation raises various questions: Work of hidden hands?

Malaysia

20-year-old labourer faces trial over sexual assault of six-year-old boy, child pornography

Malaysia

Do not sacrifice integrity for personal gains or remuneration – Sultan Nazrin